Back to Feed
Fintech▲ 50
MeiraGTx Acquires Gene Therapy Asset
Globenewswire·
MeiraGTx has announced the acquisition of botaretigene sparoparvovec (bota-vec) through an asset purchase agreement with Johnson & Johnson. This gene therapy asset is intended for the treatment of X-linked Retinitis Pigmentosa (XLRP), a rare inherited eye disease. The acquisition signifies MeiraGTx's strategic expansion into new therapeutic areas and strengthens its pipeline of innovative treatments for genetic disorders.
Tags
acquisition
product
legal
Original Source
Globenewswire — www.globenewswire.comRelated in Fintech
X Money Tests Whether Social Commerce Can Hold Consumer Deposits
PYMNTSBeaten-down digital asset treasury names lead crypto stock surge as bitcoin hits
CoinDeskBitcoin retakes $78,000 as Trump declares Hormuz ‘open and ready for business’
The BlockSen. Blumenthal presses DOJ and Treasury on Binance monitor amid Iran sanctions
The Block